Thus, we hypothesized that MDK‐targeted therapy might be efficacious in treating tumors with various SCLC cells as MDK may target non‐NE‐type SCLC cells, thereby indirectly inhibiting NE‐type SCLC cell proliferation. Here, MDK is linked to small cell lung carcinoma.